Colorectal Cancer Clinical Trials in Denver

Showing 181-200 of 252 trials

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

NCT03035253

The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX. OMP-305B83 is a humanized bispecific monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread. The study is sponsored by OncoMed Pharmaceuticals, which is referred to as OncoMed or the Sponsor.

Metastatic Colorectal Cancer

OncoMed Pharmaceuticals, Inc.16 participantsStarted Dec 2016

Duarte, California, United States • Denver, Colorado, United States • Fort Collins, Colorado, United States +3 more locations

COMPLETEDPhase 3< 1 mile

A Study in Second Line Metastatic Colorectal Cancer

NCT01183780

The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.

Colorectal Cancer

Eli Lilly and Company1,072 participantsStarted Dec 2010

Sedona, Arizona, United States • Tucson, Arizona, United States • Fayetteville, Arkansas, United States +210 more locations

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

A Study in Second Line Metastatic Colorectal Cancer

Colorectal Cancer Trials in Other Cities

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps

Study of Ruxolitinib in Colorectal Cancer Patients

Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection

Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

Other Conditions in Denver